Osteogenic sarcoma exhibits a bimodal distribution, with the significant second peak in incidence occuring in the seventh and eighth decades of life. Osteosarcoma in the elderly can also be attributed to Paget’s disease or previous radiotherapy. The expectation that these elderly patients may not tolerate aggressive modern chemotherapy means that those who develop OS over the age of 40 years are excluded from current treatment trials. As a result, remarkably little is known about the outcome for this age group.1

• 1. Grimer RJ, Cannon SR, Taminiau AM, et al.: Osteosarcoma over the age of forty. Eur J Cancer 2003;39(2):157-163.